Posthoc analysis 2 phase III RCTs of ABAtacept x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA+MTX Rx pts were compared &

Aug 30, 2023 3:00 pm
Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
Dr. John Cush
Social Author Name
RheumNow
Tweet Content
Posthoc analysis 2 phase III RCTs of ABAtacept x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA+MTX Rx pts were compared & there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies https://t.co/lBJrPzm5S1 https://t.co/RM542Hl8Fu
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×